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There is an urgent need for the development of new antifungal agents. A facile in vivo model that evaluates libraries of
chemical compounds could solve some of the main obstacles in current antifungal discovery. We show that Candida
albicans, as well as other Candida species, are ingested by Caenorhabditis elegans and establish a persistent lethal
infection in the C. elegans intestinal track. Importantly, key components of Candida pathogenesis in mammals, such as
filament formation, are also involved in nematode killing. We devised a Candida-mediated C. elegans assay that allows
high-throughput in vivo screening of chemical libraries for antifungal activities, while synchronously screening against
toxic compounds. The assay is performed in liquid media using standard 96-well plate technology and allows the study
of C. albicans in non-planktonic form. A screen of 1,266 compounds with known pharmaceutical activities identified 15
(;1.2%) that prolonged survival of C. albicans-infected nematodes and inhibited in vivo filamentation of C. albicans.
Two compounds identified in the screen, caffeic acid phenethyl ester, a major active component of honeybee propolis,
and the fluoroquinolone agent enoxacin exhibited antifungal activity in a murine model of candidiasis. The whole-
animal C. elegans assay may help to study the molecular basis of C. albicans pathogenesis and identify antifungal
compounds that most likely would not be identified by in vitro screens that target fungal growth. Compounds
identified in the screen that affect the virulence of Candida in vivo can potentially be used as ‘‘probe compounds’’ and
may have antifungal activity against other fungi.
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Introduction
The discovery of substantial commonality between micro-
bial pathogenesis in mammals and nonvertebrate model
hosts, such as the nematode Caenorhabditis elegans, has
provided the foundation for the development of high-
throughput genetic analysis of microbial virulence factors
in live animal models (reviewed in [1,2]). We sought to extend
the use of the C. elegans infection models to identify chemical
compounds with antifungal activity against Candida species,
the most common human pathogenic fungus.
Candida spp. are the fourth most common cause of
nosocomial blood-stream infections, and disseminated can-
didiasis continues to have an attributable mortality rate of
over 25% [3]. The mortality rate for device-associated Candida
infection can be even higher [4]. In the United States, the
overall excess cost attributable to candidemia is estimated at
$1 billion per year and the average cost of candidemia for a
single episode is about $40,000 (1997 United States dollar)
[5,6]. However, efforts to identify new antifungal compounds
have been hindered by the fact that most compounds that
have antifungal activity in vitro are also toxic to mammalian
cells. A facile bioassay compatible with high-throughput
screening technologies, which simultaneously evaluated li-
braries of chemical compounds for antifungal activity and
host toxicity in the context of a whole-animal Candida
infection model, could solve some of the main obstacles in
current antifungal discovery.
Here, we show that Candida albicans, as well as other Candida
strains, can kill C. elegans. We used these ﬁndings to develop a
C. elegans-based infection model that is performed in standard
96-well plates in liquid media, thereby enabling automated
addition of compounds. An important feature of the assay is
that the ﬁrst assay endpoint is nematode survival, which
automatically eliminates highly toxic compounds that affect
nematode viability. Moreover, important components of
Candida pathogenesis in mammals are involved in nematode
killing, and ﬁlamentation becomes apparent as the nematode
dies, providing a second clinically relevant endpoint. We
demonstrate how this model enables the screening of a
chemical library for compounds that prolong nematode
survival or inhibit Candida ﬁlamentation. Importantly, the
screen identiﬁes compounds that prolong survival in a
hematogenous murine model of candidiasis.
Results
Killing of C. elegans by Candida Species
C. elegans nematodes eat microorganisms, but they die when
fed a variety of human bacterial and fungal pathogens [1,2]. In
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out by transferring nematodes from lawns of Escherichia coli
strain OP50 (their normal laboratory food) to lawns of
pathogenic bacteria or yeast grown on solid agar media.
However, screening chemical libraries using an agar-based C.
elegans-killing assay is not readily compatible with the use of
robots for ﬁlling assay plates and pin transfer of compounds,
homogeneous distribution of chemicals in the medium, or the
use of automated plate readers or automated screening
microscopes to monitor nematode survival. We therefore
sought to develop a C. elegans–Candida spp.-killing assay that
could be performed in liquid media. We found that when
wild-type L4 stage N2 nematodes were fed Candida spp. on
solid brain–heart infusion (BHI) medium for 2 h and then
were transferred to a liquid medium consisting of 20% BHI
and 80% M9 minimal medium, the longevity of the worms
was signiﬁcantly reduced compared to worms not infected
with Candida (Figure 1A). We tested different times of
exposure to Candida spp. on solid BHI medium (from 5 min
to 24 h) and in all cases the longevity of the worms was
signiﬁcantly reduced compared to uninfected worms (un-
published data).
Although Candida spp. killed wild-type C. elegans in liquid
medium, the killing did not occur rapidly enough to prevent
the production of progeny produced by 3- and 4-d-old
hermaphroditic nematodes. The presence of a brood in the
assay mix made it difﬁcult to score the viability of the
infected parents. Indeed, in the assay described above and
shown in Figure 1A, it was necessary to painstakingly remove
progeny nematodes that survived beyond the L1 or early L2
developmental stage. Production of progeny during the assay
had another undesirable consequence in the scoring of the
assay; namely, Candida-infected wild-type nematodes ex-
hibited signiﬁcant matricidal death (over 30%) involving
the premature hatching of eggs in the C. elegans uterus (which
is not necessarily directly associated with an infectious-like
process) around day 3 of the experiment. To avoid these
problems associated with progeny production, we substituted
C. elegans glp-4 mutants for wild-type in the Candida spp. killing
assay. C. elegans glp-4 mutant animals have normal morphology
and brood sizes at 15 8C, but do not make gonads and are
unable to produce eggs at 25 8C [7–10]. As shown in Figure
1A, Candida spp. also killed glp-4 nematodes, but the rate of
killing was signiﬁcantly slower than for wild-type worms
(Figure 1A), similar to results reported previously for the
killing of glp-4 and other sterile mutants by bacterial
pathogens.
Although glp-4 mutant worms could have potentially been
used in an antifungal screening assay, we sought to increase
the rate of killing of the glp-4 mutant by utilizing glp-4;sek-1
double mutant worms. SEK-1 encodes a mitogen-activated
protein kinase kinase that functions directly upstream of the
C. elegans homolog of the mammalian p38 mitogen-activated
protein kinase that was shown previously to be an important
component of the C. elegans defense response to pathogens
[7,11]. As shown in Figure 1A, the C. elegans glp-4;sek-1 double
mutant was signiﬁcantly more susceptible to Candida than the
glp-4 mutant (p , 0.001), suggesting that the C. elegans
homolog of the mammalian p38 mitogen-activated protein
kinase (which is involved in mammalian response to
candidiasis [12]) plays a signiﬁcant role in the C. elegans
response to Candida. This ﬁnding is consistent with the
observation that sek-1 mutants are more susceptible to a
variety of pathogens [7,11]. When glp-4 and glp-4l;sek-1
mutants were moved from OP50 plates to pathogen-free
liquid media, their survival was not signiﬁcantly different
from N2 worms in the presence of E. coli in liquid media
(unpublished data). Notably, when we exposed glp-4;sek-1
worms to DAY185 for 2 h and then moved to lawns of an E.
coli OP50 strain that expresses green ﬂuorescent protein
(GFP), over 70% of the worms had no GFP-expressing
bacteria in their intestine, suggesting that the grinder is still
operational, at least in the majority of the nematodes.
Because the glp-4;sek-1 mutant was similarly susceptible to a
variety of C. albicans strains as well as to the non-albicans
strains Candida krusei and Candida parapsilosis (Figure 1B),
because it did not produce progeny, and because we found it
compelling to study Candida pathogenesis in immunocom-
promised nematodes (in some ways analogous to candidiasis
in immunocompromised humans), we utilized the glp-4;sek-1
strain in all of the further studies described below.
Progression of Candida Filamentation within C. elegans
Candida yeast cells have the ability to develop ﬁlaments that
are usually differentiated to hyphae (long continuous germ
tubes separated by true septin rings) or pseudohyphae (chains
of distinct cells that fail to separate). Development of human
candidiasis involves adhesion to the substratum (which allows
the yeast to colonize surfaces, such as the gastrointestinal
tract and intravascular catheters), development of bioﬁlm,
and formation of hyphae and pseudohyphae [13–15]. Fila-
mentation is instrumental in Candida virulence in mammals;
nonﬁlamentous mutants of C. albicans are highly attenuated
[16]. Candida hyphae invade host tissues and exert mechanical
force through cells and tissues, enabling escape of C. albicans
from the host bloodstream [17,18]. Notably, there is signiﬁ-
cant coregulation between adherence, bioﬁlm, and ﬁlament
pathways [15,19,20]. For example, genes involved in bioﬁlm
formation are required for hyphal development, while
ﬁlaments are a prominent feature of C. albicans bioﬁlms that
support bioﬁlm integrity [4,21–23].
Persistence in the intestine appears to be a critical ﬁrst step
during Candida infection in C. elegans. Indeed, nematodes
exposed to Candida lawns are unable to clear the Candida
infection when they are transferred to Candida-free liquid
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Author Summary
Candida spp. are among the most significant causes of nosocomial
infections, and disseminated candidiasis continues to have an
attributable mortality rate of over 25%. For this reason, we have
developed a liquid media assay using the model nematode
Caenorhabditis elegans as a model organism for Candida infection.
The worms are infected on solid media lawns and then moved to
pathogen-free liquid media. Unless antifungal compounds are
added to the wells, the majority of worms die within 3–4 d. This
model is similar to the infection process in humans, in that Candida
cells are able to produce filaments, which are essential for the
infection process in humans. We used this pathogen model to
create a semi-automated, high-throughput screen using C. elegans
to evaluate the antifungal effectiveness of many types of chemical
compounds. Through this process, we have identified three
compounds that we show have varying degrees of antifungal
activity in C. elegans, in vitro, and in mice.media (Figures 2 and S1). Even when nematodes were exposed
to Candida lawns for as little as 5 min and then transferred to
pathogen-free liquid media or lawns of E. coli OP50, 100% of
the nematodes remain colonized (unpublished data). As a
result, Candida cells ﬁll the nematode pharynx and intestine
(Figure S1B and unpublished data). Also, we placed the worms
on lawns of C. albicans strain MLR62, a strain that con-
stitutively expresses GFP, and then we moved them onto the
non-GFP parent strain DAY185. Over a 24-h period, the GFP-
expressing Candida cells were displaced by non-GFP-express-
ing cells, suggesting that Candida cells are not too big to be
defecated.
To evaluate the hypothesis that bioﬁlm formation and
ﬁlamentation are involved in C. elegans killing, we infected C.
elegans with C. albicans kem1 and suv3 mutants that are
defective in hyphal production [24]. As shown in Figure 3,
C. elegans killing by kem1 (strain MLR74) and suv3 (strain
GKO443) mutants was signiﬁcantly attenuated compared to
the isogenic parental strain DAY185 (p ¼ 0.0008 and p ,
0.0001, respectively for the two mutants, compared to the
wild-type strain DAY185). There was no signiﬁcant difference
in killing between the wild-type and strains in which the kem1
and suv3 mutations had been reconstituted with wild-type
alleles by homologous recombination (unpublished data).
Notably, it appears that the interface between solid and liquid
is important for ﬁlamentation, as it is not observed during
Candida–C. elegans interaction on solid media (unpublished
data and [25]). Because the C. albicans bioﬁlm defective
mutants that were used in our studies were also defective in
ﬁlamentation, the study of the role of Candida bioﬁlm in C.
elegans pathogenesis requires further experimentation.
Interestingly, in the absence of C. elegans, none of the
Candida species tested in the liquid assay formed ﬁlaments.
Nevertheless, after nematodes died, extensive ﬁlamentation
was observed in the colonized worms with numerous
ﬁlaments exiting through the nematode cuticle (Figure 4A
and 4B). Moreover, after the integrity of the cuticle was
breached, the yeast cells did not dissipate within the liquid
medium, but rather remained connected, resulting in C.
elegans ‘‘ghosts’’ in which the transition from mostly yeast-like
Candida cells to the ﬁlaments outlined where the cuticles used
to be (Figure 4C–4F).
We used a C. albicans reporter strain that expresses yeast-
enhanced GFP (yEGFP3) from the promoter for the gene
Hyphal Wall Protein 1 (HWP1) to evaluate whether true
hyphae are formed during the infectious process in C. elegans.
This strain confers developmental expression of yEGFP3 in
germ tubes and hyphae, but not in yeasts or pseudohyphae
[18,26,27]. As shown in Figure 5, yEGFP3 expression was
observed in ﬁlaments as they penetrated the nematode
cuticle, conﬁrming that C. albicans forms hyphae in the course
of C. elegans infection. No yEGFP3 expression was detected
prior to ﬁlamentation.
Figure 2. Intact C. albicans Cells Persist within the C. elegans Intestine
C. elegans strain glp-4;sek-1 L4 worms were transferred from OP50 to C. albicans for 30 min and then moved to Candida-free liquid media for 6 d when
the worms were photographed. Intact yeast cells are seen within the (A) proximal and (B) distal intestine. White arrows in (A) point to the pharyngeal
grinder organ. Black arrows point to the intestinal lumen. Scale bars are 31.58 lm.
doi:10.1371/journal.ppat.0030018.g002
Figure 1. Killing of C. elegans after Exposure to Candida Species
(A) N2, glp-4, or glp-4;sek-1 L4 nematodes feeding on E. coli OP50 were transferred to C. albicans strain DAY185 for 2 h and then transferred to pathogen-
free liquid medium. Dead nematodes were counted and removed daily. N2 worms transferred from E. coli OP50 directly to liquid media were used as
control. Survival of glp-4;sek-1 is significantly shorter compared to the strain glp-4 (p , 0.001).
(B) Survival of C. elegans glp-4;sek-1 feeding on lawns of C. albicans ATCC#90028, C. parapsilosis ATCC#20019, or C. krusei ATCC#6258. p , 0.001 for each
of the yeast strains compared to control nematodes that were exposed to E. coli OP50 (;65 nematodes/group).
doi:10.1371/journal.ppat.0030018.g001
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To develop a system that allows high-throughput screening
for antifungal compounds, we ﬁrst evaluated whether estab-
lished antifungals prolong the survival of nematodes infected
with Candida spp. For this, we used different C. albicans isolates
as well as non-albicans strains, including those used as
reference strains by clinical microbiology laboratories [28].
Notably, all strains tested were susceptible to amphotericin B
and caspofungin, but had different susceptibilities to ﬂuco-
nazole [24,26,29,30] (Table 1). We found that antifungals that
are active against a particular Candida strain resulted in
prolongation of C. elegans survival when the nematodes were
infected with the relevant Candida strain (Figure 6A–6D).
Caspofungin, a fungicidal agent that is active against Candida
bioﬁlm [31,32], and also the fungicidal agent amphotericin B,
were the most active agents tested in prolonging nematode
survival to C. albicans strain MLR62 (Figure 6A), C. krusei
American Type Culture Collection (ATCC) #6258 (Figure 6B),
C. parapsilosis ATCC#20019 (Figure 6C and 6D), and C. albicans
ATCC#90028 (unpublished data). In the case of C. krusei
ATCC#6258, the most resistant to ﬂuconazole among the
strains we tested, caspofungin and amphotericin B were more
effective than ﬂuconazole (in both cases p , 0.0001; Figure
6B). Antifungal agents were also effective at lower concen-
trations; for example, caspofungin was effective at concen-
trations as low as 1 lg/ml in the case of C. albicans strain MLR62
(p , 0.0001). Since ﬁlament formation was only seen after the
Candida cells overwhelmed and killed the nematode, there
were signiﬁcantly fewer nematodes with ﬁlaments in the wells
that contained antifungal compounds (unpublished data).
Interestingly, at high concentrations, the beneﬁcial effect
of ﬂuconazole was lost and the nematodes died faster than
untreated infected worms. Fluconazole up to 32 lg/ml was
effective in prolonging survival of nematodes exposed to the
ﬂuconazole-susceptible strain C. parapsilosis ATCC#20019, but
at higher concentrations (100 lg/ml) nematode survival was
diminished, even compared to the nematodes in the un-
treated control group (p ¼ 0.01; Figure 6D). Probably this
toxicity is present at even lower concentrations, but the
beneﬁcial effect from the antifungal activity outweighs the
toxic effect. For example, when nematodes were exposed to
the ﬂuconazole-resistant strain C. krusei ATCC#6258, ﬂuco-
nazole at 32 lg/ml not only had no effect on nematode
survival, but killing in the ﬂuconazole group was signiﬁcantly
faster than untreated worms (p ¼ 0.02; Figure 6B). Taken
together, these observations suggest that the C. elegans–
Candida model can be used for the concurrent screen for
antifungal activity and host toxicity.
We alsoevaluated the effect of antifungal agents inreducing
fungal burden in the nematode intestine. For example, in a
representative experiment, after 48 h, untreated C. elegans
infected with C. albicans MLR62 had an average of 170.8 6 63.5
colony-forming units (cfu) per worm, whereas caspofungin-
treated animals (at 8 lg/ml) had almost cleared the infection
with an average of 0.3 6 0.2 cfu per worm (p , 0.001).
Fluconazole and amphotericin B also signiﬁcantly decreased
the concentration of Candida cfu in the nematodes, and
Figure 4. Progression of Filamentation
The images show C. elegans glp-4;sek-1 nematodes infected by C.
albicans strain DAY185 for 2 h and then moved into pathogen-free liquid
media. On day 1, dead worms were moved to fresh wells containing
liquid media and allowed to incubate until day 6 (A and B), or day 8 (C–
F). (A, C, and E) are the light-field images and (B, D, and F) are fluorescent
images that show the filaments stained with Concanavalin A-Alexafluor,
which binds to polysaccharides. Scale bars are 100 lm (A and B) and
199.9 lm (C–F).
doi:10.1371/journal.ppat.0030018.g004
Figure 3. Candida Biofilm Formation and Filamentation Is Associated
with C. elegans Killing
Survival of C. elegans glp-4;sek-1 animals in liquid pathogen-free media
after feeding for 2 h on C. albicans mutants with disruptions in kem1
(strain MLR74) or suv3 (strain GKO443). p ¼ 0.0008 and p , 0.0001,
respectively, for the mutants compared to the parental strain C. albicans
DAY185 (;65 nematodes/group).
doi:10.1371/journal.ppat.0030018.g003
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ment with antifungals was effective in clearing the worm
intestine of visible Candida cells (unpublished data).
Antifungal Compounds Identified Using the C. elegans–
Candida-Killing Assay
To facilitate adaptation of the C. elegans–Candida-killing
assay to screening chemical libraries for antifungal com-
pounds, we used C. albicans strain MLR62 that expresses GFP
(linked to the constitutively active TEF1 promoter) and that
exhibits similar killing kinetics to the parent strain DAY185
in the C. elegans assay. Using this strain, nematodes exposed to
compounds that have signiﬁcant antifungal efﬁcacy exhibited
sinusoidal movement and no green ﬂuorescence in the
intestine at the endpoint of the assay (Figure 7A), whereas
nematodes exposed to compounds without antifungal efﬁ-
cacy did not move, were rod-shaped, exhibited high levels of
intestinal ﬂuorescence (Figure 7B), and developed ﬁlaments
(Figure 7C).
As an initial test of the C. elegans–Candida compound
screening assay, we utilized libraries of compounds made
available through the Institute of Chemistry and Cell Biology
(ICCB) at Harvard Medical School that include known
compounds that affect diverse cellular pathways as well as
the United States Food and Drug Administration approved
drugs that are known to be safe and bioactive in humans
Figure 5. Filamentation Involves the Formation of True Hyphae
Fluorescent microscopy of C. elegans glp-4;sek-1 nematodes after feeding for 2 h on C. albicans strain HGFP3 transformed with pHWP1GFP3 that
expresses green fluorescence in a hyphae-specific manner. Worms were transferred to Candida-free liquid media for 2 d (A–C) or 6 d (D–F). Green
fluorescence is seen in hyphal cells coming out of the nematode as they penetrate the nematode cuticle. Fluorescence is shown in (B and E). (C and F)
show overlap images. Scale bars are 16.16 lm (A–C) and 31.72 lm (D–F).
doi:10.1371/journal.ppat.0030018.g005
Table 1. C. albicans Strains Used in This Study
Candida Strain Description Relevant Characteristics or Phenotype Reference
DAY185 Arg
þ Ura
þ His
þ reference strain Forms meshwork comprised almost exclusively of long hyphae MIC: 0.5 lg/ml for
amphotericin B, 2 lg/ml for fluconazole and caspofungin
[24]
MLR28 KEM1 reconstituted strain Restored the ability to form normal hyphae [24]
GKO443 suv3 Biofilm-defective mutant that is defective in hypha production [24]
MLR3 SUV3 reconstituted strain Produced thick biofilms containing hyphae and excluded calcofluor from the ba-
sal cell layers
[24]
MLR74 kem1 deletion mutant Biofilm-defective mutant that is defective in hypha production [24]
MLR62 GFP-expressing WT GFP gene linked to the constitutively active TEF1 promoter [29]
C. albicans ATCC#90028 WT Isolated from blood, Iowa MIC: 2 lg/ml for amphotericin B and 1 lg/ml for cas-
pofungin
[28]
C. krusei ATCC#6258 WT Isolated from sputum of patient with bronchomycosis, Sri Lanka MIC: 2 lg/ml for
amphotericin B, 32 lg/ml for fluconazole, and 0.5–2 lg/ml caspofungin
[28]
C. parapsilosis ATCC#22019 WT Isolated from case of sprue, Puerto Rico MIC: 2 lg/ml for amphotericin B, 2 lg/
ml for fluconazole, and 0.5–2 lg/ml caspofungin
[28]
C. albicans HGFP3 Transformed with pHWP1GFP3 Expresses GFP in a hyphae-specific manner [26]
WT, wild-type.
doi:10.1371/journal.ppat.0030018.t001
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compounds and identiﬁed 15 (;1.2%) that prolonged
nematode survival and completely or almost completely
inhibited ﬁlamentation (Table S1). An additional 57
(;4.5%) compounds prolonged nematode survival but had
no or minimal effect on ﬁlamentation (Table S1). To the best
of our knowledge, the C. elegans screen identiﬁed all of the
compounds among the 1,266 tested with established, clinically
documented antifungal activity against Candida (Table S1).
Among the known antifungals, ketoconazole and butocona-
zole were among the most effective compounds identiﬁed
(Table S1).
We selected three compounds identiﬁed in the screen,
which are not established antifungals, for further analysis. By
design, we selected compounds that have a positive safety
proﬁle in mammals and exhibit variable efﬁcacy in the C.
elegans assay, including compounds that both affected or did
not affect ﬁlamentation. The three compounds selected for
further evaluation were caffeic acid phenethyl ester (CAPE),
enoxacin, and lapachol (Figure 8 and Table S1).
CAPE is a major active component of propolis, a natural
antimicrobial resinous product derived from plants, which is
collected and used by honeybees to seal cracks or large
potentially infectious objects (such as carcasses) that honey-
bees cannot remove from their hives ([33,34] and Table S1).
Enoxacin, a ﬂuoroquinolone antibiotic, was shown previously
to marginally enhance the in vitro antifungal activity of
amphotericin B and mepartricin [35]. Lapachol is a naph-
thoquinone found in the seeds and heartwood of tropical
plants that exhibits anti-leishmanicidal activity [36–38].
Enoxacin did not inhibit C. albicans ﬁlament formation in
the C. elegans-killing assay.
To determine whether CAPE, enoxacin, and lapachol play a
role in mammalian virulence, we evaluated their efﬁcacy in
Figure 6. Antifungals Prolong the Survival of C. elegans glp-4;sek-1 Nematodes Infected by Candida spp. and Evaluation of Antifungals in the C. elegans
Assay Allows the Concomitant Evaluation of Toxicity
Nematodes were infected with Candida for 2 h and then moved to pathogen-free liquid media in the presence of antifungals or PBS. Dead worms were
counted and removed daily.
(A) C. albicans strain MLR6. p , 0.0001 for caspofungin (8 lg/ml), amphotericin B (16 lg/ml), and fluconazole (32 lg/ml).
(B) C. krusei strain ATCC#6258. p , 0.0001 for caspofungin (8 lg/ml) and amphotericin B (16 lg/ml).
(C) C. parapsilosis ATCC#20019. p , 0.0001 for caspofungin (8 lg/ml), amphotericin B (16 lg/ml), and fluconazole (32 lg/ml).
(D) C. parapsilosis ATCC#20019. The p-values are 0.0001 for 4 lg/mL, ,0.0001 for 32 lg/mL, 0.01 for 100 lg/mL (;65 nematodes/group).
doi:10.1371/journal.ppat.0030018.g006
Figure 7. Phenotypic Assay Detects Compounds with Antifungal Activity
After exposure to strain C. albicans MLR62, C. elegans glp-4;sek-1 nematodes were pipetted into 96-well plates that contained compounds from chemical
libraries. Nematodes exposed to compounds that had antifungal efficacy (in this case, CAPE) had no fluorescence within the intestine (A), whereas
nematodes exposed to compounds without antifungal efficacy did not demonstrate any movement (B) and developed filaments outside the
nematodes (C). Roughly 25 worms were used per well.
doi:10.1371/journal.ppat.0030018.g007
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After tail vein injection of 1 3 10
6 blastospores, both CAPE
and enoxacin prolonged the survival of mice inoculated with
C. albicans strain DAY185 (Figure 9). Among these three
compounds, CAPE, which was the most effective agent in the
C. elegans screen, was also the most effective agent in the
murine assays (p ¼ 0.008, compared to the control of mice
that received placebo). Notably, intravenous enoxacin was
effective in once-a-day dosing of 25 mg/kg (p ¼ 0.03; 12 mice
per group), whereas CAPE was not statistically effective in
once-a-day dosing (unpublished data). Lapachol (150 mg/kg)
was not active in the mouse model (unpublished data),
consistent with previous work that suggested that lapachol
may be transformed into inactive metabolite(s) or neutralized
in mammals [36–38].
All three compounds were also evaluated in vitro for their
activity in Candida bioﬁlm formation. CAPE strongly inhibited
both ﬁlamentation and bioﬁlm formation (Figures 10 and S2
and Text S1). Interestingly, lapachol also exhibited a modest
effect on bioﬁlm formation, suggesting that metabolites of
lapachol that are not transformed into inactive metabolite(s)
or neutralized in mammals [36–38] may be useful antifungal
agents. Of note is that the antifungal activity of the three
compounds tested is most likely not due to their ability to
inhibit the growth of yeast. Among the three compounds,
only CAPE inhibited growth of C. albicans in vitro, and that
was at a minimum inhibitory concentration (MIC) of 64 lg/
ml, which was higher than the concentration (33 lg/ml) used
in the C. elegans screen. Moreover, CAPE was effective in the C.
elegans–Candida assay to a concentration as low as 4 lg/ml
(unpublished data). Enoxacin and lapachol did not inhibit the
growth of C. albicans strain DAY185 at the highest concen-
tration tested (256 lg/ml).
To evaluate for toxicity, CAPE, enoxacin, and lapachol
were evaluated in vitro using sheep erythrocytes [7] and in
vivo using glp-4;sek-1 worms in liquid media with E. coli OP50.
Neither CAPE nor lapachol hemolyzed the red blood cells, as
compared to DMSO and Triton X-100 controls, though
enoxacin exhibited a marginal amount of hemolysis; however,
none of the three compounds had any acute toxicity to
uninfected C. elegans glp-4;sek-1 worms (unpublished data).
Discussion
The objective of the studies detailed in this paper was to
develop a semi-automated, high-throughput, whole-animal C.
elegans assay that can be used to identify chemical compounds
with antifungal activity. Key features of the C. elegans assay are
that it allows concurrent evaluation of toxicity and antifungal
activity and that it identiﬁes compounds that target impor-
tant pathways associated with human Candida infection,
including ﬁlament formation. Moreover, the assay allows
the study of Candida cells that are in non-planktonic form and
identiﬁcation of antifungal compounds in a system where
both the pathogen and the host can be genetically manipu-
lated.
The C. elegans whole-animal screen has several advantages
compared to in vitro screens that use planktonic cells. Some
virulence traits are induced only in the host, and therefore
Figure 8. Chemical Compounds Identified Using the C. elegans–Candida Screen Tested in a Murine Model of Hematogenous Candidiasis
(A) CAPE, (B) enoxacin, and (C) lapachol (from http://pubchem.ncbi.nlm.nih.gov).
doi:10.1371/journal.ppat.0030018.g008
Figure 9. Compounds Identified in the C. elegans Screen Have Activity in
a Murine Model of Hematogenous Candidiasis
Survival of mice after tail vein injection of 1 3 10
6 blastospores of C.
albicans DAY185. Mice that received intravenous injection of CAPE (400
mg/kg once as a loading dose, followed by 200 mg/kg maintenance
twice daily) or enoxacin (80 mg/kg loading dose, followed by 40 mg/kg
maintenance twice daily) survived significantly longer compared to
control mice that received placebo (p ¼ 0.008 and 0.04, respectively).
There were 16 mice in each group.
doi:10.1371/journal.ppat.0030018.g009
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these virulence traits may require detection in vivo. Also, the
whole-animal approach provides two relatively unambiguous
assay endpoints in the survival/death of the worms and
ﬁlamentation, and allows the use of liquid-handling robots
for ﬁlling assay plates and for pin transfer of compounds
from library stock plates to assay plates. The current rate-
limiting step in the assay is the manual scoring of worm
viability and ﬁlament formation. Thus far, scoring of live/
dead and ﬁlamented/nonﬁlamented worms has been done by
direct human observation of movement and morphology of
the nematodes on a microscope or by reviewing microscopic
images. A quantiﬁable automated scoring assay that is
compatible with the use of high-throughput automated
screening microscopes is currently under development and
would greatly increase the throughput of the assay. Also, the
delivery of a standard number of worms in each well would
further enhance the uniformity of the assay. This is possible
using a commercially available worm-dispensing robot.
Moreover, in the future, we believe that it will be possible
to robotically dispense both Candida and C. elegans to the wells,
thereby eliminating the labor-intensive infection and wash
steps.
The C. elegans assay has many advantages compared to
screens using mammalian models. The study of pathogenesis
in mammals is complicated by difﬁculty of handling, long
reproductive cycles, small brood sizes, complexity of mam-
malian hosts, high cost, and ethical considerations. In vivo
models for Candida bioﬁlm are particularly cumbersome and
expensive, as they usually entail the placement of vascular
catheters in rabbits [39] or rats [40,41]. Overall, the whole-
animal C. elegans screen can help identify compounds that
most likely would not be identiﬁed by in vitro screens or
would be too costly and inefﬁcient using an in vivo mammal
approach. In addition to the Candida assay, members of our
group have screened libraries of chemical compounds to
identify those that have antimicrobial activity against C.
elegans that are persistently infected with the human
opportunistic pathogen Enterococcus faecalis [7].
However, it should be noted that the use of C. elegans for the
identiﬁcation of antimicrobial agents also has obvious
limitations. First, it is unlikely that the use of C. elegans (or
other invertebrate model hosts) will completely eliminate
toxic compounds, even though there is a reasonable
correlation between the toxicities of a variety of compounds
in mammals and C. elegans [7,42–44]. In addition, the small size
that makes C. elegans less expensive and amenable to high-
throughput screens makes it very difﬁcult to use this model to
study pharmacokinetic variables such as impact of protein
binding, absorption, and distribution that are automatically
assayed in other, larger animal models.
In addition to providing a facile system for screening
chemical libraries for antifungal compounds, the experi-
ments detailed above support the hypothesis that natural
Figure 10. In Vitro Efficacy of CAPE, Enoxacin, and Lapachol in Biofilm Formation
DAY185 formed biofilms on silicone squares in the presence of DMSO in PBS (A and F), caspofungin (B and G), CAPE (C and H), enoxacin (D and I), or
lapachol (E and J). Silicone squares were observed for filament formation with a 403oil emersion objective (A–E) and stained with concanavalin A-Alexa
488 to identify the cell membranes of DAY185 with confocal microscopy (F–J). All three compounds significantly decreased the dry mass of the silicone
pads (p ¼ 0.020 for caspofungin, CAPE, and lapachol; and p ¼ 0.029 for enoxacin compared to DMSO in PBS control) (K).
doi:10.1371/journal.ppat.0030018.g010
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evolution and maintenance of virulence-related genes in
pathogenic human fungi [8,45]. In previous work from our
laboratories, we showed that Cryptococcus neoformans, another
important human opportunistic fungal pathogen, is also a
potent C. elegans pathogen, supporting previous conclusions
that the pathogenic potential of C. neoformans may have
evolved as a by-product of avoiding predation by soil
organisms, including nematodes and amoebae that feed on
yeasts [46]. Thus, even though C. albicans is not necessarily
found in the same environment as C. elegans, other fungal
pathogens are found in the soil, and the interactions between
C. elegans and fungi in general can be seen as a representation
of the evolutionary arms race between fungi and soil-borne
predators such as C. elegans [47]. Interestingly, however, C.
neoformans and Candida use different approaches to kill C.
elegans. Cryptococcal cells, which are larger than Candida cells,
do not persist in the nematode intestine, and nematodes
exposed to cryptococcal lawns are able to defecate the
cryptococcal cells upon transfer to liquid media and thus can
clear the cryptococcal infection ([8] and unpublished data). In
contrast, Candida, a common colonizer of the intestinal track
of humans, establishes a persistent infection in the C. elegans
intestine, forms bioﬁlm, dissolves nematode tissues, and
breaks through the nematode cuticle by forming an impres-
sive network of ﬁlaments (Figures 2, 4, and 5).
It is expected that the C. elegans–Candida-killing assay will
not only identify compounds that affect the growth of the
pathogen in vitro, but also compounds that affect the
virulence of the pathogen in vivo, or, even immuno-modulate
the host. For example, CAPE is known to inhibit NfkappaB
[48] in mammals, and murine mouse studies suggest that it
has immunomodulatory effects in vivo [49,50]. Since C. elegans
appears not to have an NF-kB-like protein, if CAPE also
affects C. elegans immunity, the mechanism presumably does
not involve NF-kB inhibition. Since the compounds identiﬁed
through this screen have no obvious similarities with current
classes of antifungals and thus may have a different
mechanism of action, combination of these compounds with
established antifungal agents could have additive or syner-
gistic action that should be studied further.
Materials and Methods
Strains and media. The Candida strains used in these experiments
are summarized in Table 1 or described in the text. Yeast cultures
were maintained on yeast peptone dextrose (YPD) (Difco, http://
www.vgdusa.com/DIFCO.htm), agar, or as frozen stocks. The C. elegans
strains were propagated on E. coli strain OP50 or E. coli strain HB101
using established procedures (detailed below and in [7,51]).
C. elegans liquid medium killing assays. Candida strains were
inoculated in 2 ml of YPD and grown at 30 8C for 24 h. Lawns were
prepared by spreading 10 ll of each culture on 35-mm tissue culture
plates (BDFalcon, http://www.bdbiosciences.com) containing solid
BHI media (Difco) with kanamycin (45 lg/ml), ampicillin (100 lg/
ml), and streptomycin (100 lg/ml). The plates were incubated at 30 8C
for 24 h followed by 25 8C for 24 h. glp-4;sek-1 and glp-4 worms were
grown at 15 8C until they reached the L2 stage, and then they were
transferred to 25 8C for 24 h. N2 wild-type worms were grown at 15 8C
for 72 h, until they reached the L4 stage. Approximately 100 worms
were picked onto each lawn and allowed to feed for 30 min to 2 h.
The worms were washed off the plates with M9 buffer and allowed to
crawl on unseeded BHI plates to remove yeast cells from their
cuticles. Roughly 70–80 worms were then picked to wells in a six-well
microtiter dish that contained 1.5 ml liquid medium of 79% M9
buffer, 20% BHI, 10 lg/ml cholesterol in ethanol, and 90 lg/ml
kanamycin. The plates were incubated at 25 8C overnight and then
examined at 24-h intervals for survival. Worms were considered dead
and removed when they did not respond to being touched by a
platinum wire pick.
C. elegans ﬁlamentation staining. C. albicans strains DAY185 and
HGFP3 lawns were prepared, and C. elegans glp-4;sek-1 worms exposed
to C. albicans as described above for the killing assays. The worms were
then transferred to the liquid media described above in both the
presence and absence of 32 lg/ml ﬂuconazole. At 24, 48, 144, and 192
h, 20–40 worms exposed to DAY185 were stained in 200 llo f1 0lM
FUN-1 (Invitrogen, http://www.invitrogen.com) and 25 lg/ml Con-
cavalin A-Alexaﬂuor 488 (Invitrogen) for 45 min [52]. Pictures were
taken with a confocal laser microscope (TCS NT, Leica Microsystems,
http://www.leica-microsystems.com). FUN-1 is a ﬂuorescent yellow dye
that is absorbed by metabolically active fungal cells and ﬂuoresces red
when illuminated with 480 nm (ﬂuorescence emission). Concanavalin
A-Alexaﬂuor (ﬂuorescence emission at 519 nm) is a ﬂuorescent green
dye that binds to polysaccharides and stains ﬁlaments.
Evaluation of Candida cells within the nematode intestine. MLR62
and DAY185 lawns were prepared as above. An OP50-GFP strain was
grown in LB media in the presence of ampicillin (100 lg/ml), instead
of streptomycin and spotted on nematode growth media (NGM) agar
plates. For the ﬁrst experiment, sek-1;glp-4 worms were exposed to
MLR62 for 1 h, washed thoroughly, and then pipetted onto DAY185
for 2 h. The worms were then moved to pathogen-free liquid media
and photographed on days 0 and 1 with the confocal laser microscope
mentioned above. For the second experiment, sek-1;glp-4 worms were
placed on DAY185 for 2 h, thoroughly washed, and then pipetted
onto OP50-GFP NGM plates. Worms were thoroughly washed and
then photographed with a confocal laser microscope at 2, 24, and 48
h. Additionally, living and dead worms on day 1 were moved to
pathogen-free liquid media in the presence of kanamycin (90 lg/ml)
and monitored for hyphae formation.
Evaluation of fugal burden within C. elegans. The number of C.
albicans cfu in C. elegans was quantiﬁed based on the protocol detailed
in [45,53] with a few modiﬁcations. C. albicans strain MLR62 lawns
were prepared on BHI as described above. C. elegans glp-4;sek-1 worms
were exposed to the lawns for 30 min and then moved to liquid media
and incubated at 25 8C in the presence or absence of antifungal
agents. At appropriate time points, three groups of ten worms each
were washed twice in 8-ll drops of M9 medium on BHI agar plates, in
order to remove surface Candida. Each group of ten worms was then
disrupted using a Pellet Pestle Motor (Kontes, http://www.
kimble-kontes.com) and plated on YPD agar containing kanamycin
(45 lg/ml), ampicillin (100 lg/ml), and streptomycin (100 lg/ml). The
plates were incubated for 48 h at 30 8C and colonies were counted.
Statistical signiﬁcance was determined by the Mann-Whitney test
using STATA6 statistical software (Stata, http://www.stata.com). A p-
value of less than 0.05 was considered to be signiﬁcant.
Screen of compound library in C. elegans. For testing the efﬁcacy of
chemical compounds, C. albicans strain MLR62 was inoculated into 2
ml of YPD and grown at 30 8C for 24 h; 10 ll of the culture was spread
on 35-mm tissue culture plates (BDFalcon) containing BHI agar
(Difco) with kanamycin (45 lg/ml), ampicillin (100 lg/ml), and
streptomycin (100 lg/ml). The plates were incubated at 30 8C for 24
h. C. elegans animals at the L4 developmental stage (grown as detailed
above under C. elegans liquid medium killing assays) were transferred
from a lawn of E. coli HB101 onto C. albicans lawns on BHI medium,
incubated at 25 8C for 30 min, and then pipetted in 50 ll into 96-well
plate wells that contained 100 ll liquid media (79% M9 buffer, 20%
BHI media, 10 lg/ml cholesterol in ethanol, and 90 lg/ml kanamycin).
C. elegans glp-4;sek-1 nematodes were pipetted into 96-well plates that
contained compounds from chemical libraries. Library 1361 was
assembled by Biomol. It contains well-characterized compounds that
affect many different aspects of cellular pathways. The NINDS
custom collection (plates 501–503) was put together by MicroSource
Discovery Systems for the National Institute of Neurological
Disorders and Stroke (NINDS), the Huntington Disease Society of
America (HDSA), the Amyotrophic Lateral Sclerosis (ALS) Associa-
tion, and the Hereditary Disease Foundation (HDF). It mostly
contains FDA-approved drugs. The Prestwick library (plate 1569)
contains compounds that are known to be safe and bioactive in
humans. The majority of the compounds are marketed drugs (details
available at http://iccb.med.harvard.edu).
On day 6, nematodes were evaluated for survival, ﬁlament
formation, and optical density. The plates were incubated at 25 8C
and examined on day 6 for survival with a Nikon SMZ645 dissecting
microscope, and images were obtained using a CellWorx High
Content Cell Analysis System (Applied Precision, http://www.
appliedprecision.com) at 43 magniﬁcation. Dead worms were
counted but not removed. Worms were considered dead if they had
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well being tapped. Each compound was also scored by the number of
dead worms in the well that developed hyphea (Table S1).
Compounds were considered to have completely or almost com-
pletely inhibited ﬁlament formation if fewer than 25% of the dead
worms in the well developed hyphea. Compounds were categorized as
having a minimal effect on ﬁlament formation if 25%–75% of the
dead worms developed hyphea. The compounds that had no effect on
ﬁlament formation allowed over 75% of the dead worms to form
hyphea.
Approximately 25 nematodes were used to analyze each chemical
compound tested. Two controls were used in all plates. The positive
control was the antifungal caspofungin (which allows .75% survival
at day 6). Phosphate-buffered saline (PBS) was the negative control
(,25% of nematodes in PBS are alive at day 6). In this pilot screen, we
considered a compound as a ‘‘hit’’ when survival in the compound
well was 50% and above of the median survival of the control wells.
Evaluation of MIC. Cells were maintained in YPD (1% yeast
extract, 2% peptone, and 2% dextrose) at 80 8C until used. The MIC
was evaluated for each of the above compounds according to the
Clinical and Laboratory Standards Institute (formerly the National
Committee for Clinical Laboratory Standards, NCCLS) microdilution
protocol (M27-A) [28].
Hemolysis assay. CAPE, enoxacin, and lapachol were evaluated for
hemolysis of sheep erythrocytes as described by Moy et al. [7]. DMSO
and Triton X-100 were used as controls.
Compound toxicity in uninfected glp-4;sek-1 worms. To test
whether CAPE, enoxacin, and lapachol were toxic to the worms at
the concentration used in the hemolysis assay, glp-4l;sek-1 L4s were
prepared as described above. The nematodes were moved from E. coli
OP50 to pathogen-free liquid media containing 2% DMSO or 2%
Triton X-100 or 100 lg/ml CAPE, enoxacin, or lapachol. The worms
were incubated for 4 h at 25 8C; at hourly intervals dead worms were
counted and removed.
Murine models of virulence. BALB/c mice (22–24 g, female, Charles
River Laboratories) were used in all studies. In brief, C. albicans strain
DAY185 was grown at 30 8C with shaking overnight in YPD to late-log
phase. The yeast cells were centrifuged, washed in PBS, and re-
suspended to a concentration of 5 3 10
6 blastospores/ml (measured
with a hemocytometer). 200 ll of this suspension were inoculated into
the lateral tail vein (1 3 10
6 blastospores). In all mammalian
experiments, the concentration of yeast cells in the inoculum was
conﬁrmed by plating serial dilutions and enumerating cfus 24–48 h
later. The murine protocols were approved by the Massachusetts
General Hospital Committee on Research, Subcommittee on Re-
search Animal Care and special attention was given to minimize the
suffering of the mice.
In vitro bioﬁlm growth on silicone pads. The effect of CAPE,
lapachol, and enoxacin on bioﬁlm growth on silicone pads was
evaluated as described by Richard et al. [24] and Nobile et al. [41]. The
C. albicans strain DAY185 was inoculated in 2 mL of YPD and grown at
30 8C for 24 h. The DAY185 culture was diluted into SD media plus 50
mM glucose to an OD600 of 1.0. After the 90-min incubation and PBS
wash, caspofungin (positive control), CAPE, enoxacin, and lapachol
were added to fresh media at 2 lg/mL, 30 lg/mL, 13.3 lg/mL, and 16.1
lg/mL, respectively.
Microscopic visualization of silicone pads. The silicone pads were
visualized as reported in [24,29]. DAY185 cells were incubated at 37
8C for 60 h on silicone squares in SD media with 50 mM glucose.
Bioﬁlms were stained with 25 lg/ml Concavalin A-Alexaﬂuor 488
(Invitrogen) for 1 h in the dark. Pictures were taken with a confocal
laser microscope (TCS NT, Leica Microsystems).
Bioﬁlm dry mass measurements. The bioﬁlm dry mass was
evaluated as described by Nobile et al. [29]. Statistical signiﬁcance
was determined by the Mann-Whitney test using STATA 6. A p-value
of less than 0.05 was considered to be signiﬁcant.
Statistical analysis. Murine and C. elegans-killing curves were
plotted, and estimation of differences (log-rank and Wilcoxon tests)
in survival analyzed with the Kaplan-Meier method performed using
STATA 6. A p-value of less than 0.05 was considered to be signiﬁcant.
Supporting Information
Figure S1. Candida Species Accumulate in the C. elegans Intestine
(A) C. elegans nematode strain glp-4;sek-1 exposed to C. parapsilosis
strain ATCC# 22019 for 2 h and then moved to microbe-free liquid
media. 1 d later, there were a signiﬁcant number of yeast cells within
the nematode resulting in distention of the nematode intestine. The
round structure (white arrows) is the pharyngeal grinder organ, which
functions to disrupt ingested organisms. Black arrows with borders
point to the intestinal lumen.
(B) As the infection within the nematode progresses, the nematode
cells are essentially replaced by yeast cells, and staining of nematodes
with FUN-1 shows yeast cells to be metabolically active (C. elegans glp-
4;sek-1 nematode 4 d after infection with C. parapsilosis strain
ATCC#22019).
Found at doi:10.1371/journal.ppat.0030018.sg001 (1.6 MB TIF).
Figure S2. In Vitro Efﬁcacy of CAPE, Enoxacin, and Lapachol Bioﬁlm
on the Surfaces of Wells of Microtiter Plates
When evaluated using the XTT reduction assay, CAPE and lapachol
inhibited the formation of bioﬁlm (A), while all three compounds had
an affect in pre-formed bioﬁlm (B).
Found at doi:10.1371/journal.ppat.0030018.sg002 (58 KB TIF).
Table S1. Compounds Identiﬁed through a Pilot Screen in C. elegans
Found at doi:10.1371/journal.ppat.0030018.st001 (349 KB DOC).
Text S1. Supplemental Methods and Reference
Found at doi:10.1371/journal.ppat.0030018.sd001 (22 KB DOC).
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The protein sequences from the TrEMBL database (http://www.ebi.ac.
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